- Home
- JHX vs GMAB Comparison
JHX vs GMAB Comparison
Compare JHX & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHX
- GMAB
- Stock Information
- Founded
- JHX 1888
- GMAB 1999
- Country
- JHX Ireland
- GMAB Denmark
- Employees
- JHX N/A
- GMAB N/A
- Industry
- JHX Building Materials
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- JHX Industrials
- GMAB Health Care
- Exchange
- JHX Nasdaq
- GMAB Nasdaq
- Market Cap
- JHX 13.4B
- GMAB 15.0B
- IPO Year
- JHX N/A
- GMAB N/A
- Fundamental
- Price
- JHX $36.13
- GMAB $20.59
- Analyst Decision
- JHX Hold
- GMAB Buy
- Analyst Count
- JHX 3
- GMAB 8
- Target Price
- JHX N/A
- GMAB $43.00
- AVG Volume (30 Days)
- JHX 67.3K
- GMAB 1.5M
- Earning Date
- JHX 11-12-2024
- GMAB 11-06-2024
- Dividend Yield
- JHX N/A
- GMAB N/A
- EPS Growth
- JHX N/A
- GMAB 14.35
- EPS
- JHX 1.01
- GMAB 10.80
- Revenue
- JHX $3,935,900,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- JHX $1.87
- GMAB $30.31
- Revenue Next Year
- JHX $10.17
- GMAB $16.49
- P/E Ratio
- JHX $35.69
- GMAB $18.52
- Revenue Growth
- JHX 5.47
- GMAB 17.75
- 52 Week Low
- JHX $29.88
- GMAB $20.50
- 52 Week High
- JHX $43.57
- GMAB $32.89
- Technical
- Relative Strength Index (RSI)
- JHX 60.35
- GMAB 25.31
- Support Level
- JHX $31.79
- GMAB $21.90
- Resistance Level
- JHX $33.60
- GMAB $23.47
- Average True Range (ATR)
- JHX 0.95
- GMAB 0.45
- MACD
- JHX 0.51
- GMAB -0.12
- Stochastic Oscillator
- JHX 92.97
- GMAB 3.03
About JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.